Dr. Reddy’s Laboratories Ltd. has firmly denied a recent media report alleging that the company has cut workforce costs by 25% amid margin pressure linked to Revlimid. In a regulatory filing to the stock exchanges dated April 14, 2025, the pharmaceutical major stated that the information published in the April 13 edition of Business Standard is factually incorrect.
The article had claimed that the company had taken cost-cutting measures, including workforce-related adjustments, to offset margin strain resulting from its generic Revlimid operations. Dr. Reddy’s, however, categorically denied these assertions.
“The company does not comment on market speculation and affirms that no such event or development requiring disclosure under SEBI’s Listing Regulations has taken place,” said K Randhir Singh, Company Secretary and Compliance Officer.
The company reiterated its commitment to prompt and accurate disclosures in accordance with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements. Dr. Reddy’s also clarified that there is currently no information that necessitates regulatory disclosure regarding the reported claims.
This clarification comes amidst increased scrutiny of pharmaceutical companies managing pricing and margin pressures in the generics market. Dr. Reddy’s has maintained that any material information will be disclosed transparently to investors and the public.
